Dobutamine Infusions for Heart Failure

Primary Recommendations

The European Society of Cardiology recommends dobutamine for patients with acute decompensated heart failure who have documented severe systolic dysfunction with low cardiac output and signs of hypoperfusion, or for those with persistent congestion refractory to diuretics and vasodilators when systolic blood pressure is too low (<90-100 mmHg) to tolerate vasodilators alone 1, 2, 3
The American College of Cardiology recommends against using dobutamine in normotensive patients (SBP >110 mmHg) with acute pulmonary edema, as vasodilators are the preferred therapy in this scenario 2

The European Society of Cardiology warns that dobutamine has not been shown to improve survival and may increase mortality risk, particularly in patients with coronary artery disease 1
The American Heart Association recommends against using dobutamine routinely in patients without evidence of decreased organ perfusion 3

The European Society of Cardiology recommends starting dobutamine when patients have documented severe systolic dysfunction with low cardiac output and signs of hypoperfusion, such as cold/clammy skin, acidosis, declining renal function, or altered mentation 1, 4
The American College of Cardiology recommends considering dobutamine for patients with persistent congestion or pulmonary edema refractory to diuretics and vasodilators at optimal doses 4

The European Society of Cardiology recommends starting dobutamine at 2-3 μg/kg/min without a loading dose, and increasing by 2-2.5 μg/kg/min every 10-15 minutes based on hemodynamic response 1, 4
The American Heart Association recommends monitoring systolic blood pressure, urine output, signs of perfusion, heart rate, and arrhythmias during dobutamine infusion 1

The European Society of Cardiology recommends continuous ECG telemetry for atrial and ventricular arrhythmias, and blood pressure monitoring (invasive arterial line strongly recommended in hypotensive patients) during dobutamine infusion 1, 4, 6
The American College of Cardiology recommends monitoring urine output (target >100 mL/h in first 2 hours), signs of perfusion, and cardiac index (if invasive monitoring available, target >2.0 L/min/m²) during dobutamine infusion 5, 6

The European Society of Cardiology recommends withdrawing dobutamine as soon as adequate organ perfusion is restored and/or congestion reduced, and gradual tapering by 2 μg/kg/min decrements to prevent rebound hypotension 1, 4, 6

The American College of Cardiology recommends combining dobutamine with norepinephrine when mean arterial pressure needs pharmacologic support, after adequate fluid challenge 4, 5
The European Society of Cardiology recommends considering low-dose dopamine (2-3 μg/kg/min) in combination with higher doses of dobutamine, though evidence for renal benefit is limited 1

The European Society of Cardiology notes that the SURVIVE trial found no difference in 180-day mortality between levosimendan and dobutamine in patients with acute decompensated heart failure, and that guideline recommendations carry Class IIb, Level C evidence from ESC and ACC/AHA 1, 3